Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma
Abstract Background Growing evidence has indicated that tumor biomarkers, including cytokeratin 19 fragment antigen 21–1 (Cyfra21–1), carbohydrate antigen 19–9 (CA19–9), carbohydrate antigen 72–4 (CA72–4), carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) were reported to b...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-5755-5 |
| _version_ | 1818161821353246720 |
|---|---|
| author | Yuchong Yang Xuanzhang Huang Likun Zhou Ting Deng Tao Ning Rui Liu Le Zhang Ming Bai Haiyang Zhang Hongli Li Yi Ba |
| author_facet | Yuchong Yang Xuanzhang Huang Likun Zhou Ting Deng Tao Ning Rui Liu Le Zhang Ming Bai Haiyang Zhang Hongli Li Yi Ba |
| author_sort | Yuchong Yang |
| collection | DOAJ |
| description | Abstract Background Growing evidence has indicated that tumor biomarkers, including cytokeratin 19 fragment antigen 21–1 (Cyfra21–1), carbohydrate antigen 19–9 (CA19–9), carbohydrate antigen 72–4 (CA72–4), carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) were reported to be commonly used in diagnosis and prognosis in esophageal squamous cell carcinoma (ESCC). However, which is the best marker for predicting prognosis remains unknown. Few papers focused on the relationship between tumor biomarkers and postoperative treatment in ESCC. Methods A total of 416 ESCC patients were enrolled in this study. The association between tumor markers and overall survival (OS) was analyzed using Kaplan-Meier method with log-rank test, followed by multivariate Cox regression models. Results The results of Cox multivariate analysis indicated that among these tumor biomarkers, CA19–9 (≥ 37 vs. < 37) [hazard ratio (HR) = 2.130, 95% confidence interval (CI) = 1.138–3.986, p = 0.018] and CEA (≥ 5 vs. < 5) (HR = 1.827, 95% CI = 1.089–3.064, p = 0.022) were the independent prognostic factors of poor OS. For the ESCC patients with CA19–9 < 37, CEA < 5 or SCC-Ag < 1.5, the surgery plus postoperative chemotherapy group had a significantly longer OS than the surgery group alone (p < 0.05), but this significant difference of OS between these two groups cannot be found in patients with CA19–9 ≥ 37, CEA ≥ 5 or SCC-Ag ≥ 1.5 (p > 0.05). Conclusions CEA and CA19–9 maybe are superior to other tumor biomarkers as prognostic indicators in ESCC. CA19–9, CEA, SCC-Ag may be useful in predicting the therapeutic effect of postoperative chemotherapy in ESCC. |
| first_indexed | 2024-12-11T16:23:52Z |
| format | Article |
| id | doaj.art-1d4e43eddb25466591349cc111c9682f |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-11T16:23:52Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-1d4e43eddb25466591349cc111c9682f2022-12-22T00:58:47ZengBMCBMC Cancer1471-24072019-05-0119111010.1186/s12885-019-5755-5Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinomaYuchong Yang0Xuanzhang Huang1Likun Zhou2Ting Deng3Tao Ning4Rui Liu5Le Zhang6Ming Bai7Haiyang Zhang8Hongli Li9Yi Ba10Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityDepartment of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical UniversityAbstract Background Growing evidence has indicated that tumor biomarkers, including cytokeratin 19 fragment antigen 21–1 (Cyfra21–1), carbohydrate antigen 19–9 (CA19–9), carbohydrate antigen 72–4 (CA72–4), carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) were reported to be commonly used in diagnosis and prognosis in esophageal squamous cell carcinoma (ESCC). However, which is the best marker for predicting prognosis remains unknown. Few papers focused on the relationship between tumor biomarkers and postoperative treatment in ESCC. Methods A total of 416 ESCC patients were enrolled in this study. The association between tumor markers and overall survival (OS) was analyzed using Kaplan-Meier method with log-rank test, followed by multivariate Cox regression models. Results The results of Cox multivariate analysis indicated that among these tumor biomarkers, CA19–9 (≥ 37 vs. < 37) [hazard ratio (HR) = 2.130, 95% confidence interval (CI) = 1.138–3.986, p = 0.018] and CEA (≥ 5 vs. < 5) (HR = 1.827, 95% CI = 1.089–3.064, p = 0.022) were the independent prognostic factors of poor OS. For the ESCC patients with CA19–9 < 37, CEA < 5 or SCC-Ag < 1.5, the surgery plus postoperative chemotherapy group had a significantly longer OS than the surgery group alone (p < 0.05), but this significant difference of OS between these two groups cannot be found in patients with CA19–9 ≥ 37, CEA ≥ 5 or SCC-Ag ≥ 1.5 (p > 0.05). Conclusions CEA and CA19–9 maybe are superior to other tumor biomarkers as prognostic indicators in ESCC. CA19–9, CEA, SCC-Ag may be useful in predicting the therapeutic effect of postoperative chemotherapy in ESCC.http://link.springer.com/article/10.1186/s12885-019-5755-5Esophageal squamous cell carcinomaPrognosisPostoperative chemotherapyTherapeutic effect; tumor biomarker |
| spellingShingle | Yuchong Yang Xuanzhang Huang Likun Zhou Ting Deng Tao Ning Rui Liu Le Zhang Ming Bai Haiyang Zhang Hongli Li Yi Ba Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma BMC Cancer Esophageal squamous cell carcinoma Prognosis Postoperative chemotherapy Therapeutic effect; tumor biomarker |
| title | Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma |
| title_full | Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma |
| title_fullStr | Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma |
| title_full_unstemmed | Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma |
| title_short | Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma |
| title_sort | clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma |
| topic | Esophageal squamous cell carcinoma Prognosis Postoperative chemotherapy Therapeutic effect; tumor biomarker |
| url | http://link.springer.com/article/10.1186/s12885-019-5755-5 |
| work_keys_str_mv | AT yuchongyang clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT xuanzhanghuang clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT likunzhou clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT tingdeng clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT taoning clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT ruiliu clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT lezhang clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT mingbai clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT haiyangzhang clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT honglili clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma AT yiba clinicaluseoftumorbiomarkersinpredictionforprognosisandchemotherapeuticeffectinesophagealsquamouscellcarcinoma |